IMPL · Impel Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.02M | $6.58M | $4.37M | - | $3.08M | $0 | $1.76M | - | $91.0K | - |
| Cost of Revenue | $2.23M | $3.22M | $2.29M | - | $1.51M | $1.74M | $1.03M | - | $0 | - |
| Gross Profit | $2.79M | $3.36M | $2.09M | - | $1.57M | $0 | $726.0K | - | $159.0K | - |
| R&D | $252.0K | $200.0K | $3.00M | - | $3.15M | $3.95M | $3.65M | - | $5.93M | $6.83M |
| SG&A | $15.35M | $19.27M | $22.04M | - | $19.66M | $18.09M | $19.80M | - | $16.34M | $8.86M |
| Total Operating Expenses | $15.60M | $19.47M | $26.52M | - | $22.81M | $22.05M | $23.45M | - | $22.27M | $14.94M |
| D&A | - | - | $272.0K | - | - | - | $310.0K | - | - | - |
| Operating Income | ($12.81M) | ($16.10M) | ($24.44M) | - | ($21.24M) | ($20.98M) | ($22.72M) | - | ($9.00M) | ($14.94M) |
| Interest Expense | $1.60M | - | - | - | - | - | $700.0K | - | - | $509.0K |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 | $0 |
| Net Income | ($13.81M) | ($7.36M) | ($30.07M) | - | ($31.10M) | ($25.20M) | ($26.97M) | - | ($9.09M) | ($15.48M) |
| EPS - Basic | ($0.58) | ($0.31) | ($1.17) | - | ($1.31) | ($1.10) | - | - | - | - |
| EPS - Diluted | ($0.58) | ($0.31) | ($1.27) | - | ($1.31) | ($1.10) | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $239.0K | $15.16M | $35.47M | $60.65M | $79.73M | $97.83M | $129.84M | $88.21M | $111.29M | $60.95M |
| Accounts Receivable | $6.59M | $6.80M | $6.28M | $7.44M | $6.13M | $4.79M | $3.89M | $1.35M | $981.0K | - |
| Inventory | $6.86M | $6.99M | $8.01M | $8.43M | $8.62M | $6.93M | $5.50M | $2.82M | $1.55M | - |
| Accounts Payable | $3.73M | $3.46M | $6.13M | $6.09M | $4.75M | $4.75M | $8.99M | $6.37M | $8.70M | $5.46M |
| Current Assets | $23.43M | $32.90M | $51.88M | $79.81M | $99.28M | $114.43M | $142.18M | $94.58M | $118.20M | $65.57M |
| Total Assets | $35.07M | $44.81M | $64.73M | $88.55M | $105.17M | $120.43M | $147.80M | $97.91M | $121.48M | $69.16M |
| Current Liabilities | $124.74M | $121.22M | $22.28M | $22.16M | $19.96M | $18.30M | $23.98M | $15.95M | $16.31M | $9.01M |
| Long-term Debt | $0 | $0 | $48.09M | $48.07M | $47.36M | $47.21M | $47.11M | $29.45M | $29.29M | $8.86M |
| Total Liabilities | $126.98M | $123.97M | $137.63M | $132.71M | $127.46M | $116.52M | $120.32M | $45.40M | $45.59M | $17.86M |
| Stockholders' Equity | ($91.91M) | ($79.16M) | ($72.91M) | ($44.16M) | ($22.29M) | $3.91M | $27.48M | $52.51M | $75.89M | $51.30M |
| Retained Earnings | ($372.35M) | ($358.53M) | ($351.18M) | ($321.11M) | ($298.07M) | ($266.97M) | ($241.77M) | ($214.80M) | ($190.06M) | ($165.03M) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($24.14M) | - | - | - | ($24.21M) | - | - | - |
| Investing Cash Flow | - | - | ($1.05M) | - | - | - | ($8.0K) | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $65.84M | - | - | - |
| CapEx | - | - | $1.05M | - | - | - | $8.0K | - | - | - |
| Free Cash Flow | - | - | ($25.19M) | - | - | - | ($24.22M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 55.6% | 51.1% | 47.7% | - | 51.1% | - | 41.3% | - | 174.7% | - |
| Operating margin | -255.0% | -244.6% | -558.9% | - | -689.2% | - | -1291.8% | - | -9889.0% | - |
| EBITDA margin | - | - | -552.7% | - | - | - | -1274.2% | - | - | - |
| Net margin | -275.0% | -111.7% | -687.7% | - | -1009.0% | - | -1533.3% | - | -9992.3% | - |
| Free cash flow margin | - | - | -576.1% | - | - | - | -1376.9% | - | - | - |
| FCF / Net income | - | - | 0.84 | - | - | - | 0.90 | - | - | - |
| R&D / Revenue | 5.0% | 3.0% | 68.7% | - | 102.4% | - | 207.5% | - | 6515.4% | - |
| SG&A / Revenue | 305.6% | 292.6% | 504.0% | - | 637.9% | - | 1125.6% | - | 17953.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -39.4% | -16.4% | -46.5% | - | -29.6% | -20.9% | -18.2% | - | -7.5% | -22.4% |
| Return on equity | 15.0% | 9.3% | 41.2% | - | 139.5% | -644.6% | -98.1% | - | -12.0% | -30.2% |
| Return on invested capital | - | - | - | - | -66.9% | -32.4% | -24.1% | - | -6.8% | -19.6% |
| Liquidity | ||||||||||
| Current ratio | 0.19 | 0.27 | 2.33 | 3.60 | 4.97 | 6.25 | 5.93 | 5.93 | 7.25 | 7.28 |
| Quick ratio | 0.13 | 0.21 | 1.97 | 3.22 | 4.54 | 5.88 | 5.70 | 5.75 | 7.15 | 7.28 |
| Cash ratio | 0.00 | 0.13 | 1.59 | 2.74 | 3.99 | 5.35 | 5.41 | 5.53 | 6.82 | 6.77 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | -0.66 | -1.09 | -2.12 | 12.07 | 1.71 | 0.56 | 0.39 | 0.17 |
| Debt / Assets | 0.00 | 0.00 | 0.74 | 0.54 | 0.45 | 0.39 | 0.32 | 0.30 | 0.24 | 0.13 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -8.0x | - | - | - | - | - | -32.5x | - | - | -29.3x |
| Equity multiplier | -0.38 | -0.57 | -0.89 | -2.01 | -4.72 | 30.80 | 5.38 | 1.86 | 1.60 | 1.35 |
| Liabilities / Assets | 3.62 | 2.77 | 2.13 | 1.50 | 1.21 | 0.97 | 0.81 | 0.46 | 0.38 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | 0.15 | 0.07 | - | 0.03 | 0.00 | 0.01 | - | 0.00 | - |
| Inventory turnover | 0.32 | 0.46 | 0.29 | - | 0.17 | 0.25 | 0.19 | - | 0.00 | - |
| Days sales outstanding | 479d | 377d | 524d | - | 726d | - | 806d | - | 3935d | - |
| Days inventory outstanding | 1123d | 792d | 1280d | - | 2087d | 1456d | 1942d | - | - | - |
| Days payable outstanding | 611d | 392d | 980d | - | 1150d | 997d | 3178d | - | - | - |
| Cash conversion cycle | 991d | 777d | 825d | - | 1663d | - | -430d | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 63.0% | - | 148.6% | - | 3286.8% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 77.4% | - | 187.5% | - | 889.9% | - | - | - | - | - |
| Operating income growth (YoY) | 39.7% | 23.2% | -7.5% | - | -136.0% | -40.4% | -131.7% | - | - | - |
| Net income growth (YoY) | 55.6% | 70.8% | -11.5% | - | -242.0% | -62.8% | -176.4% | - | - | - |
| EPS growth (YoY) | 55.7% | 71.8% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -4.0% | - | - | - | -119.2% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -312.3% | - | - | - | - | -92.4% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-03-17.
Geographic
$150.00M totalUS$150.00M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IMPEL PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.